Zealand Pharma A/s Stock
Price
Target price
€38.80
€38.80
-2.240%
-0.89
-2.240%
-
21:59 / Tradegate
WKN: A0YJW7 / Name: Zealand / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Zealand Pharma A/s Stock
A loss of -2.240% shows a downward development for Zealand Pharma A/s.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Zealand Pharma A/s stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | -2.240% | -7.826% | -14.516% | -38.693% | -37.965% | 10.804% | 62.265% |
| Saniona AB | 3.190% | -8.892% | -8.819% | 35.620% | -41.241% | 71.537% | -38.077% |
| Ocuphire Pharma Inc. | -0.590% | -15.500% | -22.120% | 273.068% | 100.951% | -3.841% | - |
| NanoViricides Inc. | 0.000% | -8.800% | -17.986% | -11.628% | 22.581% | 10.680% | -64.662% |
News
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
The GLP weight-loss space has become increasingly competitive as new players have entered what many believe is a game-changing new market that’s still in the early innings.
But getting in the game
Merlin, Inc. Common Stock Q1 Earnings Call Highlights
Key Points
- Interested in Merlin, Inc. Common Stock? Here are five stocks we like better.
- Merlin used its first public-company earnings call to spotlight its autonomous flight strategy
SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the